Low expression of the CCL5 gene and low serum concentrations of CCL5 in severe invasive group a streptococcal disease




Kailankangas, V.; Katayama, S.; Gröndahl-Yli-Hannuksela, K.; Vilhonen, J.; Tervaniemi, MH; Rantakokko-Jalava, K.; Seiskari, T.; Lönnqvist, E.; Kere, J.; Oksi, J.; Syrjänen, J.; Vuopio, J.

PublisherSpringer Nature

2025

Infection

Infection

Infection

53

1

51

59

0300-8126

1439-0973

DOIhttps://doi.org/10.1007/s15010-024-02318-6

https://link.springer.com/article/10.1007/s15010-024-02318-6

https://research.utu.fi/converis/portal/detail/Publication/456987610



Purpose: Our objective was to elucidate host dependent factors of disease severity in invasive group A Streptococcal disease (iGAS) using transcriptome profiling of iGAS cases of varying degrees of severity at different timepoints. To our knowledge there are no previous transcriptome studies in iGAS patients.

Methods: We recruited iGAS cases from June 2018 to July 2020. Whole blood samples for transcriptome analysis and serum for biomarker analysis were collected at three timepoints representing the acute (A), the convalescent (B) and the post-infection phase (C). Gene expression was compared against clinical traits and disease course. Serum chemokine ligand 5 (CCL5, an inflammatory cytokine) concentration was also measured.

Results: Forty-five patients were enrolled. After disqualifying degraded or impure RNAs we had 34, 31 and 21 subjects at timepoints A, B, and C, respectively. Low expression of the CCL5 gene correlated strongly with severity (death or need for intensive care) at timepoint A (AUC = 0.92), supported by low concentrations of CCL5 in sera.

Conclusions: Low gene expression levels and low serum concentration of CCL5 in the early stages of an iGAS infection were associated with a more severe disease course. CCL5 might have potential as a predictor of disease severity. Low expression of genes of cytotoxic immunity, especially CCL5, and corresponding low serum concentrations of CCL5 associated with a severe disease course, i.e. death, or need for intensive care, in early phase of invasive group A Streptococcal disease.


Open access funding provided by Tampere University (including Tampere University Hospital). This work was supported by Academy of Finland [grant no 308482 to JVu]; Competitive State Research Financing of the Expert Responsibility area of Turku University Hospital [grant no 8TO5/13285 to JVu, 8TO5/11162 to JVi]; Competitive State Research Financing of the Expert Responsibility area of Tampere University Hospital [grant no 9U056 to JS]; Tampere University Hospital Foundation [grant no MK234 to JS]. Work in the JK laboratory is supported by Sigrid Jusélius Foundation (Finland), Jane and Aatos Erkko Foundation (Finland), Föreningen Liv och Hälsa (Finland), Swedish Brain Foundation (Hjärnfonden), and Swedish Research Council. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. Open access funding provided by Tampere University (including Tampere University Hospital).


Last updated on 2025-28-03 at 11:01